Nectar Lifesciences to Acquire 100% Stake in Avensis Exports, Change RTA
Nectar Lifesciences will acquire 100% of Avensis Exports Private Limited for ₹24.96 lakh to enter the real estate business. The company also decided to change its RTA from KFin Technologies to Alankit Assignments to improve efficiency and reduce costs. The acquisition is expected within a month.
The acquisition is a strategic diversification into a new sector, which could have a medium-term impact on the company's overall business. The change in RTA is a routine operational change with a low impact.
The acquisition of a new business vertical (real estate) and the change of RTA for operational efficiency are positive strategic moves for the company's growth and investor services.
Nectar Lifesciences Limited announced a significant strategic move following its board meeting on March 2, 2026. The company has decided to acquire 100% of the paid-up equity share capital of Avensis Exports Private Limited (AEPL), a company primarily engaged in the real estate business.
This acquisition is aimed at diversifying Nectar Lifesciences' business portfolio and enabling its entry into the real estate sector. AEPL, incorporated on October 16, 2007, has paid-up equity share capital of ₹8,00,000 and reported nil turnover in the last three financial years. The cost of acquisition for 100% shareholding is ₹24,96,000, with the company acquiring 80,000 equity shares at ₹31.20 per share. The acquisition is expected to be completed within one month and is not considered a related party transaction.
In addition to the acquisition, the board also approved a change in the Company's Registrar and Share Transfer Agent (RTA). The RTA services will transition from M/s. KFin Technologies Limited to M/s. Alankit Assignments Limited. This change is driven by the objective to reduce service costs, enhance operational efficiency, and improve investor service experience. KFin Technologies will continue to serve until the data transition and other related procedures are completed. The board meeting commenced at 4:00 P.M. IST and concluded at 4:30 P.M. IST.
What to do with a filing like this
Nectar Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nectar Lifesciences Limited. Read the original for the full detail.